Glycopyrronium bromide

DRUG5 trials

Sponsors

Novartis, Prosonix Limited, University of Milan, Chiesi Farmaceutici S.p.A.

Conditions

COPDCOPD ExacerbationChronic Obstructive Pulmonary Disease

Phase 2

Dose Ranging Study of Glycopyrronium Bromide in Patients With Moderate or Severe Chronic Obstructive Pulmonary Disease

CompletedNCT01703624

Prosonix LimitedChronic Obstructive Pulmonary Disease

Start: 2013-05-31End: 2013-09-30Updated: 2016-03-30

Phase 3

1-year Study to Assess the Efficacy, Safety, and Tolerability of Glycopyrronium Bromide (NVA237) in Chronic Obstructive Pulmonary Disease (COPD)

CompletedNCT00929110

NovartisChronic Obstructive Pulmonary Disease

Start: 2009-06-30End: 2011-04-30Updated: 2012-08-17

A Study to Assess the Safety, Tolerability and Efficacy of NVA237 Versus Placebo

CompletedNCT01005901

NovartisChronic Obstructive Pulmonary Disease

Start: 2009-10-31End: 2010-12-31Updated: 2012-04-12

A Study Comparing Efficacy, Safety and Tolerability of the Fixed Dose Triple Combination CHF 5993 With the Fixed Dose Dual Combination CHF 1535 in Subjects With COPD

CompletedNCT04320342

Chiesi Farmaceutici S.p.A.COPD, COPD Exacerbation

Start: 2022-04-28End: 2026-01-12Updated: 2026-01-30

Phase 4

Acute Effect of Aclidinium on Hyperinflation and Ventilation Inhomogeneity in Severe COPD Patients

CompletedNCT02181023

University of MilanChronic Obstructive Pulmonary Disease

Start: 2014-06-30End: 2014-10-31Updated: 2014-10-29

Related Papers

Faster reduction in hyperinflation and improvement in lung ventilation inhomogeneity promoted by aclidinium compared to glycopyrronium in severe stable COPD patients. A randomized crossover study.

2015-11-0621 citations

Once daily glycopyrronium for the treatment of COPD: pooled analysis of the GLOW1 and GLOW2 studies

Current Medical Research and Opinion2013-10-2433 citations

Efficacy and safety of once-daily NVA237 in patients with moderate-to-severe COPD: the GLOW1 trial.

2011-12-07134 citations